Stock info Roche | Filter  Basic-Info

Stock: Roche (Swiss large cap), ISIN: CH0012032048

Last Price 262.10 Max Price 306.10
Min Price 243.70 1 Year return 0.00
Avg. Target 280.57 Expected Return 7.05 %
Sector Health Care Subsector Pharmaceuticals
Sell 3 Rating Star full 12x12Star full 12x12
Hold 2 Concensus Cons sellCons holdCons buy
Buy 2
Annual report 2015

Loading...

Contact info:Street: 1 DNA WayZip Code: South San City: BASEL,Country: SwitzerlandPhone: 1 650 225 5566Email: RocheIRNA@gene.comWebsite: www.roche.comCEO: Dr Severin SchwanCFO: Dr. Alan Hippe

Sector Review Roche

Loading...
Year Turnover Total sector Market share
2019 56,655 474,682 11.94 %
2020 53,954 469,262 11.50 %
2021 60,560 566,698 10.69 %
2022 63,965 640,029 9.99 %
2023 63,225 590,473 10.71 %

Advice Roche

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
April 06, 2025 Sanford C. Bernstein & Co Roche Buy 345.00 24.03 %
March 16, 2025 Jefferies & Co. Roche Hold 270.00 2.93 %
February 08, 2025 Goldman Sachs Roche Sell 274.00 4.34 %
February 07, 2025 Deutsche Bank Roche Sell 265.00 1.09 %
November 02, 2024 UBS Roche Hold 270.00 2.93 %
September 30, 2024 JP Morgan Roche Sell 220.00 -19.14 %
September 02, 2024 Stifel Roche Buy 320.00 18.09 %
November 28, 2024 Deutsche Bank Roche Sell 250.00 -4.84 %
November 28, 2024 Goldman Sachs Roche Sell 265.00 1.09 %
July 04, 2024 Berenberg Roche Hold 265.00 1.09 %
July 04, 2024 Jefferies & Co. Roche Hold 250.00 -4.84 %
May 19, 2024 Deutsche Bank Roche Hold 215.00 -20.88 %
May 19, 2024 JP Morgan Roche Sell 210.00 -23.76 %
April 22, 2024 HSBC Roche Buy 280.00 12.11 %
April 10, 2024 Jefferies & Co. Roche Hold 240.00 -2.54 %
February 21, 2024 JP Morgan Roche Sell 210.00 -40.14 %
February 20, 2024 Morgan Stanley Roche Hold 250.00 -17.72 %
February 20, 2024 Berenberg Roche Buy 265.00 -11.06 %
January 15, 2024 UBS Roche Hold 278.00 2.23 %
January 15, 2024 JP Morgan Roche Sell 230.00 -18.17 %
January 03, 2024 Jefferies & Co. Roche Hold 275.00 6.80 %
October 31, 2023 JP Morgan Roche Sell 245.00 -13.39 %
October 21, 2023 DZ Bank Roche Buy 291.00 6.08 %
October 21, 2023 Deutsche Bank Roche Sell 225.00 -21.47 %
October 12, 2023 Jefferies & Co. Roche Hold 285.00 9.30 %
October 11, 2023 Morgan Stanley Roche Hold 290.00 10.86 %
October 10, 2023 JP Morgan Roche Sell 260.00 0.58 %
July 14, 2023 HSBC Roche Buy 320.00 22.19 %
June 10, 2023 JP Morgan Roche Sell 275.00 20.55 %
June 10, 2023 Jefferies & Co. Roche Hold 305.00 28.36 %
May 03, 2023 Morgan Stanley Roche Hold 320.00 31.06 %
March 28, 2023 Barclays Roche Buy 270.00 16.65 %
February 21, 2023 Morgan Stanley Roche Hold 315.00 27.87 %
January 22, 2023 UBS Roche Hold 315.00 20.37 %
January 22, 2023 Goldman Sachs Roche Buy 429.00 41.53 %
January 21, 2023 Deutsche Bank Roche Sell 265.00 5.34 %
January 05, 2023 Jefferies & Co. Roche Hold 325.00 22.51 %
January 03, 2023 JP Morgan Roche Sell 275.00 11.16 %
December 29, 2022 Barclays Roche Buy 400.00 38.92 %
December 07, 2022 Morgan Stanley Roche Hold 330.00 23.95 %



News Roche

Roche Teams Up with Zealand Pharma in $5.3 Billion Push Toward Obesity Breakthrough

Swiss healthcare leader Roche has entered a strategic alliance with Danish biotech innovator Zealand Pharma , committing up to $5.3 billion to co-develop and bring to market a new obesity therapy known as petrelintide. Deal Structure and Funding: Zealand...

2008 best year, 2009 worst year for Roche

Roche-investors have very profitable for long times. Even without dividend payments the stock is one of the outperformers from as well pharmaceutical sector as the Swiss exchange. The received dividends are a cherry on the cake for investors. The matrix above...

Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics

Roche (OTCQX:RHHBY) has signed a multi-target strategic collaboration and license agreement with Shape Therapeutics. Under the terms of the agreement, Shape is eligible to receive an initial payment as well as development, regulatory and sales milestone...

Analysts expect over 2020 rising revenue Roche

For this year Roche's revenue will be around 61,6 billion CHF. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 61,47 billion CHF. Historical revenues and results Roche plus estimates 2020 SKF The analysts...

Analysts expect revenue increase Roche

Tomorrow the Swiss Roche will report its past quarters results. Over the current book year the total revenue will be 62,25 billion CHF (consensus estimates). This is slightly more than 2018's revenue of 56,85 billion CHF. Historical revenues and results Roche...

Annual reports Roche

2017 2018 2019 2020 2021

Profile Roche

Roche

(CH0012032048)/ ROG

Roche's headquarter is based in BASEL,. The core activities of Roche are in the pharmaceutical sector. Roche is leaded by CEO Dr Severin Schwan The CFO of Roche the company is Dr. Alan Hippe. Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a good investment year for Roche investors

The stock lost over the past 12 months at around 14 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 66 percent. Roche's revenues between 2011 and 2015 were relatively steady and moved between 45,5 billion CHFF and 48,15 billion CHFF. Roche's net results between 2011 and 2015 were relatively steady and moved between 10,48 billion CHFF and 11,04 billion CHFF.

Over the past 5 years the Swiss company paid out dividends. Over the past 5 years Roche's dividend yield was at around 38,05 percent per year. Over the period 2011-2015 Roche raised it's dividends per share each year. Based on the yearly higher dividend payments Roche is a kind of dividend aristocrat.

At the end of 2015 the company had around 88,51 thousand people employed.

Roche' balance mostly consists of equity

At the end of 2015 the Swiss company's balance sheet was worth 75,76 billion CHFF. At the end of 2015 the total debt positon equaled 54,78 billion CHFF. This is around 72,31 percent of the total balance sheet. At the end of 2016 the Swiss company was traded with a price/earnings-ratio of around 22. So investors paid 22 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 231,98 billion CHFF. At the end of 2015 the Swiss company had around 851 million stocks listed.

All Roche's financial reports are available here. More information about Roche can be found it's website. .


Results Roche

Results
2015
2016
2017
2018
2019
2020
Revenue
44,252
47,266
45,602
50,504
56,655
53,954
Costs
36,107
38,318
38,217
41,177
44,217
40,731
Profit
8,145
8,948
7,385
9,327
12,438
13,223
Margin of profit
18.41
18.93
16.19
18.47
21.95
24.51
ROI
42.24
40.04
32.65
38.01
41.21
39.33

Balance Roche

Balance
2015
2016
2017
2018
2019
2020
Equity
19,282
22,346
22,622
24,540
30,184
33,618
Debt
50,355
49,446
42,981
45,218
46,404
46,067
Total assets
69,637
71,792
65,603
69,758
76,588
79,685
Solvency
27.69
31.13
34.48
35.18
39.41
42.19
Cash
8,429
8,511
10,264
11,654
10,929
11,410
Cashflow
14,018
14,019
15,421
17,750
20,633
17,175
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.28
0.28
0.36
0.39
0.44
0.37

Details Roche

Details
2016
2017
2018
2019
2020
Price
276.40
232.60
246.50
243.40
314.00
Eps
10.00
8.00
10.00
14.00
15.00
Price/earnings-ratio
27.64
29.07
24.65
17.39
17.47
Dividend
7.00
7.00
7.00
8.00
8.00
Dividend %
2.53 %
3.01 %
2.84 %
3.29 %
3.05 %
Payout %
0.70
0.88
0.70
0.57
0.53
Book value
32.30
32.60
35.34
43.38
48.50
Market to book
0.12
0.14
0.14
0.18
0.19
Cashflow per stock
20.26
22.23
25.56
29.66
24.78
Stocks
692
694
694
696
693
Market Cap
191.248.80
161.389.44
171.176.50
169.347.01
181.668.32

Dividend Roche


Price info Roche

Date
Price
25 Jun 2025
262.10
20 Jun 2025
260.00
07 Jun 2025
268.20
03 Jun 2025
264.70
28 May 2025
260.90
27 May 2025
262.50
19 May 2025
259.70
09 May 2025
259.90
01 May 2025
269.30
29 Apr 2025
265.10
22 Apr 2025
255.60
09 Apr 2025
246.10
08 Apr 2025
246.10
03 Apr 2025
286.80
30 Mar 2025
296.70
27 Mar 2025
303.00
26 Mar 2025
305.70
20 Mar 2025
306.10
15 Mar 2025
305.80
12 Mar 2025
296.50
01 Mar 2025
299.20
25 Feb 2025
298.10
23 Feb 2025
298.40
18 Feb 2025
294.30
13 Feb 2025
291.70
12 Feb 2025
288.20
07 Feb 2025
289.00
05 Feb 2025
286.00
02 Feb 2025
286.00
21 Jan 2025
266.90